"Pharmaceutical speed-reading society" Huahai "grab food" 300 million anti-epileptic drugs Sansheng Guojian issue price was determined.

July 10, 2020 / Medical Information At a Glance: Hengrui "Yugatini" starts non-small cell lung cancer Phase III clinical; 8 provinces supplies start to reduce prices by more than 70% more than well-known arms enterprises winning the bid; Kangmei real-time controller Ma Xingtian was subject to mandatory measures; Oganon announced a personnel appointment; Sansheng National Health Board issue price to determine next week to open the purchase; Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Brief The General Office of the State Council issued guidance on promoting the reform of the system of supervision of the health insurance fund, and the General Office of the State Council issued guidance on promoting the reform of the system of supervision system of the medical insurance fund on the 9thmentioned deepening the supply-side reform of medical servicesThe main contents of theare to speed up the comprehensive reform of public hospitals, establish and improve the modern hospital management system, standardize the behavior of diagnosis and treatment, and constantly improve the market-oriented price formation mechanism for drugs and medical supplies, and improve the mechanism of linking the price of medical insurance payment with tender procurement(General Office of the State Council) the new version of the drug clinical trial registration and information publicity platform system online to meet the requirements of the new version of the Drug Registration Management Measures (State Administration of Market Supervision and Administration Order No27), combined with the original State Food and Drug Administration issued "on the drug clinical trial information platform announcement" (2013 No28 announcement) and the main issues in the information registration process, CDE announced that the original drug clinical trial registration and information publicity platform upgrade(CDE) 8 provincesupplies began to reduce prices by 70% more than well-known arms enterprises won the bid of Guizhou Province, Minnan State Public Resources Trading Center issued the "Yannan State orthopaedic implanted medical supplies centralized procurement announcement."more than 40 medical device manufacturers from China to participate in the bidding, 7 enterprises were shortlisted, the largest decline of 70%through public selection, bidding, bargaining and other links, the final 4 enterprises shortlisted orthopaedic implants (spinal) category supplies suppliers, 3 enterprises shortlisted orthopaedic implants (joints) category supplies suppliers, spinal supplies up to 70%, joint supplies up to 66%(The Public Resources Trading Center of Minnan County, Guizhou Province) 26 batches of drugs unqualified Shandong, Gansu Drug Administration issued a drug quality bulletin, a total of 26 batches of drugs unqualifiedof which 6 batches are preparations, the others are Chinese medicine tablets, involving white-headed, Sichuan-bea-mother, cypress and so on(Shandong, Gansu Drug Administration) Part 2 production after observation kangmei real controller Ma Xingtian was taken coercive measures on the evening of the 9th, Kangmei Pharmaceuticals issued a notice that received the company's actual controller MrMa Xingtian's family notice, MrMa Xingtian suspected of illegal disclosure, non-disclosure of important information by the public security organs to take coercive measuresaccording to the Criminal Law, "Article 161, the crime of illegal disclosure, non-disclosure of important information", in fact, the controller or sentenced to fixed-term imprisonment of not more than three years or criminal detention, and a single fine of 20,000 yuan to 200,000 yuan or less(Kangmei Pharmaceuticals announcement) three-year net profit of not less than 800 million! Pharmaceutical enterprises push equity incentive plan Erkang Pharmaceuticals released the 2020 employee shareholding plan (draft), intended to target no more than 300 employees, to raise not more than 1999.997 million yuan, involving the number of shares of the company is 1999.997 million shares, about 1% of the company's total share capital, the purchase price is set at 1 yuan / share at the same time, the employee's shareholding plan sets a challenging three-year performance appraisal target calculated that the company will need to achieve a net profit of not less than 807.5 million yuan in 2020-2022 to meet the requirements for unlocking the employee shareholding plan (Ercon Pharmaceuticals) Organon announced a personnel appointment to Announce the appointment of Deborah H Telman as general counsel of the new spin-off company Organon Organon is a new company that Moshadon announced on February 5th that it is dedicated to women's health, patented drugs and biosimilars (Pharmaceutical Rubik's Cube) Sansheng Guoke's issue price is determined to open next Monday to purchase Sansheng Guojian to issue an initial public offering of shares and to list the company board announcement, said that after the initial inquiry, the company determined that the IPO price of the company is 28.18 yuan / share, the corresponding price-earnings ratio of 75.73 times, and will start on July 13 online and off-line purchase (Pharma Rubik's Cube) Junshi Bio's stock code is no longer marked "B" Junshi Bio, which has applied to the Stock Exchange under Rule 18A.12 of the Securities Listing Rules of the Stock Exchange of Hong Kong Limited and has obtained the approval of the Stock Exchange to no longer apply to Rules 18A.09 to 18A.11 of the Listing Rules the stock code of Junshi Bio is no longer marked "B" (Junshi Bio Announcement) Part 3 Pharmaceutical Information Bayer Innovative Therapy reaches stage 3 clinical endpoint to effectively reduce the risk of death from kidney disease Bayer announced that it has reached the primary endpoint of the trial in the phase 3 clinical trial fidelio-DKD in the treatment of patients with chronic kidney disease (CKD) with type 2 diabetes added to standard care compared to placebos, finerenone can delay the first occurrence of kidney failure, reduce the risk of death from kidney disease, and slow the rate of decline in renal glomerular filtration (eGFR) (Drug Mingcond) Hengrui "Pyritini" launch edgeic phase III clinical Insight database shows that Hengrui's innovative drug "Malayacid pyritinib" started two clinical trials, one is Malayic pyritinib for the use of the HE2 gene exosome 20 mutations containing platinum chemotherapy, advanced squamous small cell lung cancer effectiveness and safety phase III clinical study; (Insight Database) Hengrui hepatitis B new drug HRS9950 launch clinical 9, Hengrui a week ago approved clinical 1 new drug HRS9950 tablets startclinical, indications for chronic hepatitis B HRS9950 is a new class of chronic hepatitis B developed by Heng Rui, the drug is TLR8 selective agonist, TLR8 is one of the members of toll receptor (Toll receptor, TLR), in vitro activity data show that HRS9950 has significant activation effect on human TLR8, but also indirectly activates adaptive immunity, further kill sepsis of liver cell infection virus (Insight Database) Colum Pharmaceuticals KL280006 Injection II Clinical Launch for the treatment of acute pain Colum Pharmaceuticals Class 1 new drug KL280006 Injection II Clinical, for the treatment of acute pain KL280006 injection scantilyse for Collon Pharmaceuticals, an optional peripheral opioid receptor agonist developed with independent intellectual rights, is an opioid analgesic achieve effective analgesia while avoiding adverse reactions of central analgesicdrugs and is intended for the treatment of acute pain (such as postoperative pain) (Insight Database) FDA approved the 6th Adamu monoanti-biosimilar drug Mylan and Concord Kirin recently jointly announced that the U.S FDA has approved Hulio (adalimuab-fkjp), the flagship product of Abbvie Humira (adalimumab, Ada Biosimilardrugs for the treatment of a variety of autoimmune diseases, including rheumatoid arthritis, juvenile isoarthritis (4 years and older), psoriasis arthritis, aggressive spina bifida, adult Crohn's disease, ulcerative colitis, and plaque-type psoriasis (Sina Pharmaceutical News) Keytruda second-line treatment of classic Hodgkin lymphoma was fda priority review, Mershadon announced that the FDA has accepted Keytruda's supplementary biologics license application, and agreed to priority review eligibility for the treatment of recurrent or refractable classic Hodgkin lymphoma adult patients PDUFA date is October 30, 2020 (Sina Pharmaceutical News) The FDA has accepted AstraZeneca's application for a new drug for Guerrero's supplement, announcing that the FDA has accepted its application for a supplementary drug for Gretelor, the English-language product name Brilinta, and has granted it priority to review it in conjunction with aspirin to reduce the occurrence of acute ischemic stroke or a short-term follow-up cerebrotic attack (Drug Mingkang) Weishi double-acting appetite receptor antagonist Dayvigo in Hong Kong, China to apply for listing! The new drug Dayvigo (lemborexant), a new insomnia drug, has been accepted by the Hong Kong Special Administrative Region Of China's Department of Health for the treatment of adult insomnia, which is characterized by difficulty falling asleep and/or sleep-sustaining, the company announced application is the first Dayvigo regulatory application in Asia outside Japan (Bio Valley) YangSen third generation TKI lung cancer target drug in China to declare clinical clinical China State Drug Administration Drug Review Center of the latest public announcement, Johnson and Johnson's Yangsen Pharmaceutical Lazertinib tablets in China to declare clinical trial applications, and access to CDE Lazertinib is a third-generation tyrosine kinase inhibitor that is being developed to treat non-small cell lung cancer patients carrying mutations in the EGFR gene (Drug Mingkang) Huahai "snatching" 300 million anti-epileptic drug Huahai Pharmaceuticals, Pribarin capsule 4 imitation listing application was accepted - and china's public medical institutions terminal Pribarin capsule sales of more than 300 million yuan in 2019, currently, only Qilu Pharmaceuticals has been rated (Minnet.com) Treasure Island Stir 6 billion injections will meet the third review of the CDE website shows that treasure island pharmaceutical industry hydrochloric acid ambromine requisite injection 4 class of generic listing application was accepted -meter net data show that in 2019 China's public medical institutions terminal sales of ammonia bromine injections nearly 6 billion yuan, while hydrochloric acid ammonia brocoma injections only Sichuan Delta Kanghuakang Pharmaceuticals and China Central Pharmaceuticals have been rated (minnet) 2 drugs first reviewed "Omeprazole intestinal tablets" into the official website of the State Drug Administration, showed that there are 3 drugs through the consistency evaluation, including Shandong New Age Pharmaceuticals "Omeprazole intestinal tablets" (10mg), China Resources Zizhu Pharmaceuticals "Miso prostol tablets" (200 sg) for the first consistent evaluation (National Drug Administration) Jasinda ERK inhibitor JSI-1187 U.S Phase I clinical trial completed the first patient-given drug Tes inda announced that JSI-1187 in the United States conducted Phase I clinical trial completed the first patient administration JSI-1187 is an oral, highly selective ERK1/2 kinase inhibitor developed to treat tumors that carry mapK kinase pathway mutations (Pharma Rubik's Cube) to invest $900 million in Mercadon to expand multispecific antibody development cooperation, The Canadian clinical biopharmaceutical company Zymeworks announced that it has signed a new license agreement with long-term partner Mercado worth more than $900 million, granting the latter the right to develop multi-antibody-specific treatment candidates using its Azymetric ™ and EFECT ™ platforms (Sina Pharmaceutical News) Sanofi and Kymera Therapeutics, in collaboration with Kymera Therapeutics, have developed protein degradation therapy for the treatment of immuno-inflammatory diseases, announced that the company has reached a multi-project strategic partnership with Sanofi to jointly develop and commercialize "first-in-class" protein degradation therapy for IRAK4 to treat immune inflammatory diseases the two companies will also collaborate on a second project that is in the early stages of development Kymera will receive $150 million in upfront payments and potential development, regulatory and sales milestone payments of more than $2 billion, as well as a share of sales for listed products (Drug Mingconde)